Tirzepatide (GIP/GLP-1 Receptor Agonist)

Mounjaro

Type 2 Diabetes ○○○○○ | SUBQ Once-Weekly

Dosing and Titration for T2DM in Adults

- Start at **2.5 mg**/week for **4 weeks**, then ↑ to **5 mg**/week
- For added glycemic control, may ↑ to **7.5 mg**/week after **≥4 week**
- For added glycemic control, may ↑ to **10 mg**/week after **≥4 week**
- For added glycemic control, may ↑ to **12.5 mg**/week after **≥4 week**
- For added glycemic control, may ↑ to **15 mg**/week after **≥4 week**

(2.5 mg/0.5 mL) — **2.5** mg, **single** dose *(once-weekly dosing)*



(5 mg/0.5 mL) — **5** mg, **single** dose *(once-weekly dosing)*

(7.5 mg/0.5 mL) — **7.5** mg, **single** dose *(once-weekly dosing)*

(10 mg/0.5 mL) — **10** mg, **single** dose *(once-weekly dosing)*

(12.5 mg/0.5 mL) — **12.5** mg, **single** dose *(once-weekly dosing)*



(15 mg/0.5 mL) — **15** mg, **single** dose *(once-weekly dosing)*

Zepbound

Weight Management 12-20% | SUBQ Once-Weekly

Dosing and Titration for Weight Management in Adults

- Start at **2.5 mg**/week for **4 weeks**, then ↑ to **5 mg**/week
  - Dose may be ↑ in 2.5 mg increments after ≥4 week on current dose
- Recommended maintenance dosages are **5**, **10**, or **15 mg**/week
  - Consider treatment response/tolerability with maintenance dose selection; If a recommended maintenance dose is not tolerated, consider lower dose

(2.5 mg/0.5 mL) — **2.5** mg, **single** dose *(once-weekly dosing)*

(5 mg/0.5 mL) — **5** mg, **single** dose *(once-weekly dosing)*

(7.5 mg/0.5 mL) — **7.5** mg, **single** dose *(once-weekly dosing)*

(10 mg/0.5 mL) — **10** mg, **single** dose *(once-weekly dosing)*

(12.5 mg/0.5 mL) — **12.5** mg, **single** dose *(once-weekly dosing)*



(15 mg/0.5 mL) — **15** mg, **single** dose *(once-weekly dosing)*

Note: Mounarjo is also available as single-use vials



✨ GLP-1 Chart PDF with Pyrls Pro! 💜

GLP-1 and GIP/GLP-1 Receptor Agonists

Dulaglutide (GLP-1 Receptor Agonist)

Trulicity — Type 2 Diabetes ●○○○ — SUBQ Once-Weekly

Dosing and Titration for T2DM in Adults and Pediatrics Ages 10+ Years

- Start at **0.75 mg**/week
- For added glycemic control, may ↑ to **1.5 mg**/week after **≥ 4 weeks***

Adults Only:

- For added glycemic control, may ↑ to **3 mg**/week after **≥ 4 weeks**
- For added glycemic control, may ↑ to **4.5 mg**/week after **≥ 4 weeks**

**In adults, the FDA prescribing information does not explicitly specify a titration duration between increasing from the 0.75 mg/week dose to the 1.5 mg/week dose*

(0.75 mg/0.5 mL)	**0.75** mg, **single** dose *(once weekly dosing)*
(1.5 mg/0.5 mL)	**1.5** mg, **single** dose *(once weekly dosing)*
(3 mg/0.5 mL)	**3** mg, **single** dose *(once weekly dosing)*
(4.5 mg/0.5 mL)	**4.5** mg, **single** dose *(once weekly dosing)*

Liraglutide (GLP-1 Receptor Agonist)

Victoza — Type 2 Diabetes ●○ — SUBQ Once-Daily

Dosing and Titration for T2DM in Adults & Pediatrics Ages 10+ Years

Adults:

- Start at **0.6 mg**/day for **1 week**, then ↑ to **1.2 mg**/day
- For added glycemic control, may ↑ to **1.8 mg**/day after **≥ 1 week**

Ages 10-17 Years:

- Start at **0.6 mg**/day
- For added glycemic control, may ↑ to **1.2 mg**/day after **≥ 1 week**
- For added glycemic control, may ↑ to **1.8 mg**/day after **≥ 1 week**

(18 mg/3 mL)	**0.6** mg, **1.2** mg, or **1.8** mg per injection *(once-daily dosing)*

Semaglutide (GLP-1 Receptor Agonist)

Ozempic — Type 2 Diabetes ●○○○ — SUBQ Once-Weekly

Dosing and Titration for T2DM in Adults

- Start at **0.25 mg**/week for **4 weeks**, then increase to **0.5 mg**/week
- For added glycemic control, may ↑ to **1 mg**/week after **≥ 4 weeks**
- For added glycemic control, may ↑ to **2 mg**/week after **≥ 4 weeks**

(2 mg/3 mL)	**0.25** or **0.5** mg per injection *(once-weekly dosing)*
(4 mg/3 mL)	**1** mg per injection *(once-weekly dosing)*
(8 mg/3 mL)	**2** mg per injection *(once-weekly dosing)*

Rybelsus — Type 2 Diabetes ●○○ — Oral Once-Daily

Dosing and Titration for T2DM in Adults

- Start at **3 mg**/day for **30 days**, then increase to **7 mg**/day
- For added glycemic control, may ↑ to **14 mg**/day* after **≥ 30 days**

The FDA prescribing information recommends **against using two 7 mg tablets to achieve 14 mg dose*

3 mg tablet *(once-daily)*	**7** mg tablet *(once-daily)*	**14** mg tablet *(once-daily)*

Wegovy — Weight Management 10-15% — SUBQ Once-Weekly

Dosing and Titration for Weight Management in Adults & Pediatrics Ages 12+ Years

Initiation and Escalation:

- Start at **0.25 mg**/week for **4 weeks** (“Weeks 1 to 4”)
- ↑ to **0.5 mg**/week for **4 weeks** (“Weeks 5 to 8”)
- Then ↑ to **1 mg**/week for **4 weeks** (“Weeks 9 to 12”)
- Then ↑ to **1.7 mg**/week for **4 weeks** (“Weeks 13 to 16”)
  - *If an escalation dose is not tolerated, consider delaying escalation 4 weeks*

Maintenance (Adults):

- Either ↑ to **2.4 mg**/week (recommended) or remain at **1.7 mg**/week based on treatment response/tolerability for “Week 17 and onwards”

Tirzepatide (GIP/GLP-1 Receptor Agonist)

Mounjaro — Type 2 Diabetes ●○○○○ — SUBQ Once-Weekly

Dosing and Titration for T2DM in Adults

- Start at **2.5 mg**/week for **4 weeks**, then ↑ to **5 mg**/week
- For added glycemic control, may ↑ to **7.5 mg**/week after **≥ 4 week**
- For added glycemic control, may ↑ to **10 mg**/week after **≥ 4 week**
- For added glycemic control, may ↑ to **12.5 mg**/week after **≥ 4 week**
- For added glycemic control, may ↑ to **15 mg**/week after **≥ 4 week**

(2.5 mg/0.5 mL)	**2.5** mg, **single** dose *(once weekly dosing)*
(5 mg/0.5 mL)	**5** mg, **single** dose *(once weekly dosing)*
(7.5 mg/0.5 mL)	**7.5** mg, **single** dose *(once weekly dosing)*
(10 mg/0.5 mL)	**10** mg, **single** dose *(once weekly dosing)*
(12.5 mg/0.5 mL)	**12.5** mg, **single** dose *(once weekly dosing)*
(15 mg/0.5 mL)	**15** mg, **single** dose *(once weekly dosing)*

Zepbound — Weight Management 12-20% — SUBQ Once-Weekly

Dosing and Titration for Weight Management in Adults

- Start at **2.5 mg**/week for **4 weeks**, then ↑ to **5 mg**/week
  - Dose may be ↑ in 2.5 mg increments after ≥ 4 week on current dose
- Recommended maintenance dosages are **5**, **10**, or **15 mg**/week
  - Consider treatment response/tolerability with maintenance dose selection; If a recommended maintenance dose is not tolerated, consider lower dose

(2.5 mg/0.5 mL)	**2.5** mg, **single** dose *(once weekly dosing)*
(5 mg/0.5 mL)	**5** mg, **single** dose *(once weekly dosing)*